JCPP Editorial Conflicts of Interest – 2011
Article first published online: 5 FEB 2011
© 2011 The Authors. Journal of Child Psychology and Psychiatry © 2011 Association for Child and Adolescent Mental Health
Journal of Child Psychology and Psychiatry
Volume 52, Issue 3, page 332, March 2011
How to Cite
(2011), JCPP Editorial Conflicts of Interest – 2011. Journal of Child Psychology and Psychiatry, 52: 332. doi: 10.1111/j.1469-7610.2011.02394.x
- Issue published online: 5 FEB 2011
- Article first published online: 5 FEB 2011
The JCPP follows the International Committee of Medical Journal Editors (ICMJE) practice regarding conflicts of interest, available at http://www.icmje.org
Editor in Chief:
Edmund Sonuga-Barke: Recent speaker board: Shire Pharma, UCB Pharma; Current & recent consultancy: UCB Pharma, Shire; Current & recent research support: Janssen Cilag, Shire, Qbtech, Flynn Pharma; Advisory Board: Shire, Flynn Pharma, UCB Pharma, Astra Zeneca; Conference support: Shire.
Tobias Banaschewski: Served in an advisory or consultancy role for Bristol Myers-Sqibb, Desitin, Lilly, Medice, Novartis, Pfizer, Shire, UCB and Viforpharma. He received conference attendance support and conference support or received speaker’s fee by Lilly, Janssen McNeil, Medice, Novartis, Shire, UCB. He is/has been involved in clinical trials conducted by Lilly, Shire and Novartis.
David Coghill: An advisory board member for Cephalon, Eli Lilly, Janssen Cilag, Pfizer, Shire, Schering-Plough and UCB; has provided consultancy for Shire; and has received research funding from Shire, Eli Lilly and Janssen Cilag.